Stoptions.aiStoptions.aiStoptions.aiStoptions.aiStoptions.ai
Powered by Amora Edge
How it worksResultsPricingMeet StoptieCompareBlog
Sign inStart free trial
Stoptions.ai
Powered by Amora Edge

Algorithmic scanning across the S&P 500 & Nasdaq 100. Stock & Options trade cards in your inbox by 9:35 AM ET every trading day.

Product
  • How it works
  • The Algorithm
  • Ticker Setups
  • Pricing
  • Morning Brief
  • Results
  • Compare tools
Account
  • Sign in
  • Start free trial
  • Give a gift
  • Dashboard
  • Settings
Company
  • About
  • Contact
  • Support
  • Blog
  • Sitemap
Legal
  • Terms of service
  • Privacy policy
  • Risk disclosure
  • Unsubscribe

© 2026 Stoptions.ai · All Rights Reserved

Not financial advice. Algo-generated setups are not personalised investment advice. Options trading involves significant risk of loss — past performance does not guarantee future results.

Chat with Stoptie
Stoptions.ai›Tickers›CRL
Last updated: Wed May 13, 2026 · 9:31 AM ET
↻ Next update: Sun May 17, 2026 · 9:31 AM ET

CRL Stock and Options Trade Setup — Charles River LaboratoriesCRL logo

S&P 500 · Life Sciences (Contract Research) · Moderate-liquidity options · Large cap · ~$10B

▲ Bullish setupHealthcareLife SciencesMedium risk↑ Score +4 vs last update
65
Amora Edge Score
65
Top 27% of today's scan
↑ +4 vs last update
Composite of EMA, RSI, RS vs SPY & volume · updated every 72h
61
CRL Win Rate
61%
9 of 15 CRL setups hit target in 2025–2026
Tracks completed Stoptions setups on this ticker since Jan 2026
Why we cover CRL

Charles River operates the dominant outsourced preclinical CRO platform globally — a position built over 80 years that is extraordinarily difficult to replicate given the regulatory expertise, proprietary research model colonies, and deep customer relationships embedded in multi-year master service agreements. Every new drug candidate that enters development anywhere in the world either uses Charles River services or a tier-2 provider that competes on price rather than capability. After a severe biotech funding drought in 2023-2024 that crushed CRO demand, biotech funding is recovering with venture capital and IPO activity normalising — the lagged demand recovery will flow through CRL's revenue with a 6-12 month offset. At current valuations, CRL prices in permanent demand destruction rather than a cyclical trough.

Score History & Signal Changelog

Preview data

This page is a living document — updated every 72 hours from the last scan. Each data point below represents one complete algorithmic snapshot.

Score progression across 4 updates
Solid = composite · dashed = components
Signal changelog
DateUpdateScoreDeltaKey change
Apr 29#1 Created55—Page created. CRL at cycle trough; biotech funding recovery beginning to show in order data.
May 4#2 Update59+4Biotech VC funding Q1 2026 at highest since 2022. CRL backlog stabilising.
May 9#3 Update62+3EMA crossover confirmed. CRO sector rotation underway vs. broader healthcare.
May 13#4 Current65+3Recovery momentum building. Valuation at cycle low pricing in no recovery.

Signal Breakdown

EMA Cross
Active
17/25
Price crossing above 21-day EMA; biotech recovery lifting CRO demand outlook
RSI Zone
Active
16/25
RSI recovering from 42 to 56 — meaningful momentum reversal from trough
RS vs SPY
Active
17/25
CRO sector outperforming broader healthcare as biotech funding recovers
Volume Surge
Holding
15/25
1.3x 20-day average; early institutional re-entry into life sciences services

Today's Trade Card

Setup
CRL $165 CALL
Expires Jul 18, 2026
Premium
$6.00
Target
+70% premium
Stop loss
-50% premium
Breakeven
$171
Win prob.
53%
Sizing: Risk <= 0.75% of account
Greeks
Delta
0.42
Theta
-0.14
IVR
30%
IVR class
Medium
Trade card available on Pro & Elite
Or start free trial →

Options Profile

Avg IV (30d)
34%
IVR range (52-wk)
18-60%
Put/call ratio
0.78
Avg daily vol.
8K contracts
Open interest
100K contracts
Next earnings
Aug 6, 2026 (est.)

Risks & Fundamentals

Every setup carries risk. Here's what could move CRL against you, plus the key stats that frame any position.

Beta
1.3
Market cap
~$10B
Risk level
Medium risk
Next earnings
Aug 6, 2026 (est.)
Key risks to monitor
  • 1.Biotech funding remaining constrained if interest rates stay elevated and risk-off sentiment persists in life sciences
  • 2.Large pharma M&A activity consolidating CRL's biggest customers, reducing outsourcing as acquirers in-source services
  • 3.Chinese CRO competition (WuXi) winning lower-end preclinical work and compressing CRL's addressable market
These are real risks to the long thesis, not a recommendation to short. Stoptions setups are short-dated and stop-protected; size accordingly.

CRL Options Setup — Frequently Asked Questions

Is CRL a good options trade today?+

Charles River Laboratories (CRL) currently has an Amora Edge Score of 65/100, ranking it top 27% of today's scan. This composite score is built from four sub-signals — EMA cross, RSI zone, relative strength vs SPY, and volume surge — each scored 0–25. The current read is a bullish setup, so the algorithm is positioned bullish (calls / call debit spreads). A score above 65 typically warrants a trade card with stop and target; below that, the setup is on the watchlist but not actionable.

What is CRL's win rate on Stoptions.ai setups?+

CRL's historical win rate on closed Stoptions setups is 61%. Win rate is calculated as the percentage of past CRL trade cards that hit their target price before stopping out. Win rate is most meaningful once a ticker has 10+ closed trades — individual ticker rates can be noisy at smaller samples. Our portfolio-wide win rate across all closed trades is the more stable benchmark.

What strike and expiry does Stoptions.ai suggest for CRL?+

The strike and expiry are shown on the trade card at the top of this page when the setup is active. Stoptions.ai algorithmically selects strikes targeting delta 0.35–0.45 and expirations 30–45 days out, adjusted for current implied volatility rank (IVR). When IVR is high, the system favors call debit spreads to limit vega risk; when IVR is low, single-leg long calls are preferred. The card includes the contract symbol, mid-price entry, stop, and target.

How often is the CRL setup updated?+

Every 72 hours we refresh CRL's Amora Edge Score and trade card. The underlying scan runs daily at 9:00 AM ET (pre-market) and 9:30 AM ET (post-open), so any new signal change is reflected within one trading session. If CRL drops below the entry threshold or the regime shifts (e.g., SPY enters a confirmed bear), the trade card is replaced with a "no setup" notice automatically.

What does the Amora Edge Score measure for CRL?+

The Amora Edge Score is a 0–100 composite of four technical sub-signals applied to CRL: (1) EMA cross — is the 20-day above the 50-day with both trending up? (2) RSI zone — is momentum in the 50–70 sweet spot, or extended/weak? (3) Relative strength vs SPY — is CRL outperforming the market over 20 sessions? (4) Volume surge — is participation above the 20-day average? Each sub-signal contributes 0–25 points. CRL currently scores 65.

How does CRL compare to other Life Sciences (Contract Research) setups?+

CRL's sector rank and percentile against other Life Sciences (Contract Research) tickers we track is shown on the /tickers index — sortable by Amora Edge Score, win rate, or sector. For direct comparison, see the "Related Life Sciences (Contract Research) Options Setups" panel above. When multiple tickers in the same sector are scoring 80+, the algorithm flags the cluster as a sector rotation signal and may upweight position sizing.

Educational content only — not personalized investment advice. Options carry substantial risk.

The Weekly · Free

Get a Friday recap including setups like CRL.

Every Friday at 4:30 PM ET — trade of the week, signals in motion, sector spotlight, methodology read. 4-minute read. Free.

No spam. One email Friday afternoon. Unsubscribe in one click.

More from Stoptions.ai
← All tickersHow the algorithm worksMorning BriefResultsPricing